HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) but lowers the price target from $20 to $13.
November 07, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Coherus BioSciences' price target has been lowered from $20 to $13 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. indicates a potential decrease in the short-term value of Coherus BioSciences' stock. However, the maintained 'Buy' rating suggests that the analyst still sees long-term potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100